Home/Pipeline/Schizophrenia Model Service

Schizophrenia Model Service

Schizophrenia

Pre-clinicalActive

Key Facts

Indication

Schizophrenia

Phase

Pre-clinical

Status

Active

Company

NeuroProof

About NeuroProof

NeuroProof is a neuroscience-focused CRO based in Göttingen, Germany, offering specialized pre-clinical screening services. Its core platform combines Microelectrode Array (MEA) recordings of neuronal network activity with advanced data analysis and pattern recognition to model neurological diseases and assess compound effects. The company serves pharmaceutical and biotech clients by providing phenotypic assays, neurotoxicity evaluations, and custom disease models, primarily using iPSC-derived neurons, to accelerate CNS drug development and reduce reliance on animal testing.

View full company profile

Therapeutic Areas

Alzheimer's Disease Parkinson's Disease Epilepsy Amyotrophic Lateral Sclerosis Schizophrenia Neuropathic Pain Fragile X Syndrome Neurotoxicity

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active
Risperidone Implant	Delpor	Phase 1b/2a / Late-stage	Active